Stephens raised the firm’s price target on NeoGenomics (NEO) to $11 from $6.50 and keeps an Overweight rating on the shares after the company announced that a North Carolina district court ruled in the company’s favor in the litigation with Natera (NTRA). The ruling grants NeoGenomics the ability to broadly commercialize RaDaR ST and removes an overhang, says the analyst, who believes the decision strengthens NeoGenomics’ positioning in oncology and helps to support more durable growth.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- Dell reports ‘beat and raise,’ Caterpillar sees big tariff impacts: Morning Buzz
- NeoGenomics’ Legal Victory and Market Potential Boosts Buy Rating
- NeoGenomics announces court ruling in its favor in lawsuit against Natera
- NeoGenomics Board Member Elizabeth Floegel Resigns
- NeoGenomics price target lowered to $11 from $12 at Piper Sandler